References
- Dodel, R. C., Y. Du, C. Depboylu, et al. 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 75: 1472–1474
- Relkin, N. R., P. Szabo, B. Adamiak, et al. 2009. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging. 30: 1728–1736
- Dodel, R., A. Rominger, P. Bartenstein, et al. 2013. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 12: 233–243
- Medpage Today. Alzheimer’s Disease: IVIG Fails in Trial (7 May 2013; accessed 20 June 2014). Available at: http://www.medpagetoday.com/Neurology/AlzheimersDisease/38939
- Dodel, R., H. Hampel, C. Depboylu, et al. 2002. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer’s disease. Ann. Neurol. 52: 253–256
- Smith, L. M., M. P. Coffey, A. C. Klaver, D. A. Loeffler. 2013. Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein. Int. Immunopharmacol. 16: 424–428
- Lutz, H. U., P. Stammler, E. Jelezarova, et al. 1996. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood. 88: 184–193
- Lutz, H. U., P. Stammler, V. Bianchi, et al. 2004. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood. 103: 465–472
- Menezes, M. C., G. Benard, M. N. Sato, et al. 1997. In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations. Int. Arch. Allergy Immunol. 114: 323–328
- Blank, M., L. Anafi, G. Zandman-Goddard, et al. 2007. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int. Immunol. 19: 857–865
- Jerne, N. K. 1974. Towards a network theory of the immune system. Ann Immunol (Paris) 125C: 373–389
- Richter, P. H. 1975. A network theory of the immune system. Eur. J. Immunol. 5: 350–354
- Kazatchkine, M. D., G. Dietrich, V. Hurez, et al. 1994. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol. Rev. 139: 79–107
- Loeffler, D. A., L. M. Smith, A. C. Klaver, et al. 2012. Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin. Comp. Med. 62: 31–36
- Balakrishnan, K., L. C. Andrei-Selmer, T. Selmer, et al. 2010. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. J. Alzheimers Dis. 20: 135–143
- Klaver, A. C., J. M. Finke, J. Digambaranath, et al. 2010. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int. Immunopharmacol. 10: 115–119
- Klaver, A. C., M. P. Coffey, L. M. Smith, D. A. Loeffler 2013. Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies. Immunol. Lett. 154: 7–11
- Wilks, S. S. 1962. Mathematical Statistics. John Wiley, New York
- Szabo, P., D. M. Mujalli, M. L. Rotondi, et al. 2010. Measurement of anti-beta amyloid antibodies in human blood. J. Neuroimmunol. 227: 167–174